March 1, 2016Journal of the American College of Cardiology128 citationsOpen Access
View Full PaperPlatelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial
Structured PICO
Does ticagrelor 60 mg twice daily achieve similar platelet inhibition compared to 90 mg twice daily in patients from the PEGASUS-TIMI 54 trial?
P
Population
Patients in the PEGASUS-TIMI 54 Trial
I
Intervention
Ticagrelor 60 mg twice daily
C
Comparator
Ticagrelor 90 mg twice daily
O
Outcome
Peak and trough platelet inhibitionsurrogate
Ticagrelor 60 mg twice daily provides similar peak and trough platelet inhibition to the 90 mg dose, providing a pharmacodynamic explanation for its clinical efficacy.
Abstract
Ticagrelor 60 mg bid achieved high levels of peak and trough platelet inhibition in nearly all patients, similar to that with 90 mg bid, helping to explain the efficacy of the lower ticagrelor dose in PEGASUS-TIMI 54.